Molina-Polo LD, Aragón CM, Casasola GJ, Galicia SR, Castillo HJ

Language: Spanish
References: 17
Page: 160-165
PDF size: 267.34 Kb.

ABSTRACT

Bladder cancer represents the second most frequent tumor of the urinary tract, is more frequent in the white population than in the black and its peak presentation is 65 years of age. The cause of this type of cancer is multifactorial. A total of 90% of all bladder tumors corresponds to transitional cell carcinoma. Intravesical immunotherapy with bacillus Calmette-Guerin (BCG) has been the criterion Standard treatment for superficial carcinoma since 1976.
Materials and Methods. A total of 45 patients from the “20 de Noviembre” National Medical Center of the ISSSTE was evaluated who presented with superficial transitional cell bladder cancer, later managed with transurethral resection of the bladder using BCG and then monitored with control cystoscopy and cytology every 30 days.
Results. The total number of patients studied was 45. Thirty-eight (84%) were men and seven (16%) were women. The instilled doses of BCG oscillated between 81 and 90 mg. A total of 28.88% of all patients studied presented with recurrent tumor at 5 years. Adverse effects from BCG application were classified by group according to frequency: prostatitis, 13 patients (28.8%), epididimitis, 1 patient (2.2%), urinary urgency, 15 patients (33.3%) and hemorrhagic cystitis, 1 patient (2.2%).

REFERENCES

1. Campbell’s Urology. Patrick C. Walsh, Alan B. Retik, Thomas A. Stamey, E. Darracott Vaughan Jr. 1992; (2)281094-1136.

2. Smith’s General Urology. Emil A. Tanagho, Jack W. McAninch. Cap. 20;353:367. Ed. Lange 1995;20: 253-367.

3. Bohle A, Jochman D. Intravesical Immunotherapy with bacillus Calmette-Guérin, facts, figures and results. Ed. Urban & Fischer Munchen and Jena 2000.

4. Lamm DL, Blumestein BA, Crissman JD et al. Maintenance Bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study. J. Urology 2000;163:1124-1129.

5. Kondylis FI, Demirci S, Ladaga L et al. Outcomes after intravesical bacillus Calmette-Guérin are not affected by substaging of high grade T1 transitional cell carcinoma. J. Urology 2000;163:1120-1123.

6. Brake M, Loertzer R et al. Recurrence and progression of stage T1 grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guérin. J. Urology 2000; 163:1697-1701.

7. Catalona WJ, Ratliff TL. Bacillus Calmette-Guérin and superficial bladder cancer. Surg Ann 1990;22: 363.

8. Cookson MS, Sarodsy M. Management of stage T1 bladder cancer with intravesical bacillus Calmette- Guérin therapy. J Urol 1992;148:797.

9. Herr HW et al, Progression of stage T1 bladder tumors after intravesical bacillus Calmette-Guérin. J Urol 1991;145:40.

10. Hudson MA et al. Single curse versus maintenance bacillus Calmette-Guérin therapy for superficial bladder tumors: A prospective randomized trial. J Urol 1987;138:295.

11. Camacho F et al. Treatment of superficial bladder cancer with intravesical BCG. Proc Am Soc Clin Oncol 1980;21:359.

12. Gilbert HA et al. The natural history of papillary transitional cell carcinoma of the bladder and its treatment in an unselected population on the basis of histologic grading. J Urol 1978;119:488.

13. Heney NM et al. Superficial bladder cancer: Progression and recurrence. J Urol 1983;130:1083.

14. Herr HW, Laudone VP, Withmore WF. An overview of intravesical therapy for superficial bladder tumors. J Urol 1987;138:1363.

15. Herr HW et al. Superficial bladder cancer treated with bacillus Calmette-Guérin: A multivariate analysis of factors affecting tumor progression. J Urol 1989; 141:22.

16. Lamm DL et al. Complications of bacillus Calmette- Guérin immunotherapy. Urol Clin North Am 1992; 19:565.

17. Soloway MS et al. Diagnosis and management of superficial bladder cancer. Semin Surg Oncol 1989; 5:247.